Dr Reddy’s Laboratories Ltd has received USFDA approval for ‘Tosymra’ spray which is used to treat acute migraine with or without aura in adults.
The medicinal spray previously known as DFN-02 is formulated using a proprietary novel excipient known as Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action. As of January 2019, the product is yet to be commercialized.
Company Profile : Dr Reddys Laboratories Ltd
Leave a Reply